Compare DMAC & DENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DMAC | DENN |
|---|---|---|
| Founded | 2000 | 1953 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 457.2M | 318.8M |
| IPO Year | N/A | 1989 |
| Metric | DMAC | DENN |
|---|---|---|
| Price | $9.69 | $6.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $15.50 | $5.45 |
| AVG Volume (30 Days) | 529.4K | ★ 2.3M |
| Earning Date | 11-12-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $457,212,000.00 |
| Revenue This Year | N/A | $6.56 |
| Revenue Next Year | N/A | $1.56 |
| P/E Ratio | ★ N/A | $31.54 |
| Revenue Growth | N/A | ★ 0.93 |
| 52 Week Low | $3.19 | $2.85 |
| 52 Week High | $9.30 | $7.66 |
| Indicator | DMAC | DENN |
|---|---|---|
| Relative Strength Index (RSI) | 71.42 | 66.16 |
| Support Level | $7.76 | $6.13 |
| Resistance Level | $9.23 | $6.20 |
| Average True Range (ATR) | 0.66 | 0.02 |
| MACD | 0.13 | -0.04 |
| Stochastic Oscillator | 78.29 | 83.33 |
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Denny's Corp is America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees. Geographically operates in USA states as well as globally like Canada, Mexico, Guatemala, Indonesia, United Kingdom, New Zealand and others. Maximum revenue is from USA and Canada.